Exelixis Inc (NAS:EXEL)
$ 20.91 -0.32 (-1.51%) Market Cap: 6.09 Bil Enterprise Value: 5.42 Bil PE Ratio: 32.52 PB Ratio: 2.90 GF Score: 92/100

Exelixis Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 01:30PM GMT
Release Date Price: $16.44 (-2.08%)
Guyn Kim
Piper Sandler & Co., Research Division - Senior Research Analyst

Good morning. Thank you all for joining us for the 34th Annual Piper Sandler Healthcare Conference. My name is Do Kim. I'm one of the Biotech Analysts here at Piper. For our next company presentation, we have Exelixis. And it's my pleasure to welcome Andrew Peters, Senior Vice President and Head of Strategy at Exelixis.

Questions & Answers

Guyn Kim
Piper Sandler & Co., Research Division - Senior Research Analyst

Andrew, maybe we could start in your area of expertise and talk about the number of collaborations, licensing deals that were done recently, primarily for assets in the early stages. Maybe you could expand on how you think about the strategic decision to go after early stage assets versus mid to late stage or a straight-out acquisition with your cash balance?

Andrew Ross Peters
Exelixis, Inc. - SVP of Strategy

Yes. So happy to get into that, and thank you for having us and presenting at the conference.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot